Access photos, images, or videos for stories in development. If you are a member of the working press and need a resource that is not available on this website, please e-mail your request to news@bms.com and we will make every effort to respond as soon as possible. Please read our terms for usage.

Key Facts updated Jan 2019

Chief Executive Officer:

Giovanni Caforio, M.D.

Headquarters:

New York City

Business:

Biopharmaceuticals

Web Address:

www.bms.com

NYSE Listing:

BMY

Net Sales:

$22.6 billion in 2018

R&D Investment:

$5.1 billion* which included the discovery and development of new medicines for patients

Principal Locations:

*This non-GAAP amount excludes significant upfront and milestone payments for business development transactions and other specified R&D items.

2018 Largest-Selling Brands:

OPDIVO^®, $6.7 billion

ELIQUIS^®, $6.4 billion

ORENCIA^®, $2.7 billion

SPRYCEL^®, $2.0 billion

YERVOY^®, $1.3 billion

BARACLUDE^®, $744 million

SUSTIVA^® franchise, $283 million

REYATAZ^® franchise, $427 million

Hepatitis C franchise, $17 million

Selected Key Products:

BARACLUDE^® (entecavir)

DAKLINZA^™ (daclatasvir)

ELIQUIS^® (apixaban)

EMPLICITI^™ (elotuzamab)

OPDIVO^® (nivolumab)

ORENCIA^® (abatacept)

REYATAZ^® (atazanavir sulfate)

SPRYCEL^® (dasatinib)

SUSTIVA^® (efavirenz)

YERVOY^® (ipilimumab)

Please click on the product links to see the Full Prescribing Information for BARACLUDE®, DAKLINZA™,ELIQUIS®, EMPLICITI™, OPDIVO®, ORENCIA®, REYATAZ®, SPRYCEL®, SUSTIVA®, and YERVOY®, including Boxed WARNINGS for BARACLUDE®, ELIQUIS®, and Boxed WARNINGS for YERVOY® regarding immune-mediated adverse reaction.

Bristol-Myers Squibb Corporate B-roll

Description

This B-roll includes a collection of footage of Bristol-Myers Squibb's campus, corporate signage, research and development, and manufacturing facilities.

Usage Rights & Restrictions

This media asset is free for editorial broadcast, print, online and radio use. It is restricted for other purposes.